Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Yu X, Chan HTC, Fisher H, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, French RR, Duriez PJ, Douglas LR, English V, Verbeek JS, White AL, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: mockridge ci. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. doi: 10.1016/j.ccell.2020.04.013. Epub 2020 May 21. Cancer Cell. 2020. PMID: 32442402 Free PMC article.
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL, Dou L, Chan HT, Field VL, Mockridge CI, Moss K, Williams EL, Booth SG, French RR, Potter EA, Butts C, Al-Shamkhani A, Cragg MS, Verbeek JS, Johnson PW, Glennie MJ, Beers SA. White AL, et al. Among authors: mockridge ci. J Immunol. 2014 Aug 15;193(4):1828-35. doi: 10.4049/jimmunol.1303204. Epub 2014 Jul 14. J Immunol. 2014. PMID: 25024386
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, Potter EA, Ardern-Jones MR, Verbeek JS, Johnson PW, Al-Shamkhani A, Cragg MS, Beers SA, Glennie MJ. White AL, et al. Among authors: mockridge ci. Cancer Cell. 2015 Jan 12;27(1):138-48. doi: 10.1016/j.ccell.2014.11.001. Epub 2014 Dec 11. Cancer Cell. 2015. PMID: 25500122 Free PMC article.
Antagonistic human FcγRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo.
Roghanian A, Teige I, Mårtensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendéus B, Cragg MS. Roghanian A, et al. Among authors: mockridge ci. Cancer Cell. 2015 Apr 13;27(4):473-88. doi: 10.1016/j.ccell.2015.03.005. Cancer Cell. 2015. PMID: 25873171 Free article.
Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo.
Tipton TR, Mockridge CI, French RR, Tutt AL, Cragg MS, Beers SA. Tipton TR, et al. Among authors: mockridge ci. Blood. 2015 Dec 10;126(24):2643-5. doi: 10.1182/blood-2015-09-671339. Epub 2015 Oct 22. Blood. 2015. PMID: 26492935 Free article. No abstract available.
47 results